I realized that it had been days since I had been on here, and it's because they just can't surprise me anymore with the levels of stupidity on the pony board and the levels of poor business capability of NTEK management. They are literally looking for diamonds in piles of horse manure. There is nothing there that will help us bring the share price back to where we are going to recover. They "can't do anything about the stock price" is BS. They CAN do something about it. Get audits done. Get better communicators running the company. Hire a CEO and CFO. Get your promises and timelines deployed when you say you will. They absolutely can control the share price, but their ineptitude and absolute lack of concern about our investment continues to rear its ugly head and this is why our investment continues to tank. I hope for all our sake that eventually they manage to actually manage. While I'm at it, I suppose, I may as well hope I win the Powerball jackpot this week. Seems about the same odds either way.
It's kind of sad in a way. Most of us are longs, and there
I realized that it had been days since I had been on here, and it's because they just can't surprise me anymore with the levels of stupidity on the pony board and the levels of poor business capability of NTEK management. They are literally looking for diamonds in piles of horse manure. There is nothing there that will help us bring the share price back to where we are going to recover. They "can't do anything about the stock price" is BS. They CAN do something about it. Get audits done. Get better communicators running the company. Hire a CEO and CFO. Get your promises and timelines deployed when you say you will. They absolutely can control the share price, but their ineptitude and absolute lack of concern about our investment continues to rear its ugly head and this is why our investment continues to tank. I hope for all our sake that eventually they manage to actually manage. While I'm at it, I suppose, I may as well hope I win the Powerball jackpot this week. Seems about the same odds either way.
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Stellar Elevates Leadership with Key Promotions to Drive Growth
Stellar Strengthens Leadership Team for Future Success The new Executive Vice Presidents, Senior Vice President, and Vice Presidents will assume leadership roles this month. Stellar, an integrated design-build firm, proudly announces a strategic expansion of its leadership team, marking an important milestone in the company's ongoing growth and development. CEO Brian...
Continue ReadingRevolutionizing Fashion: Pixelz's Digital Twins Transform AI
Transforming Fashion Content Creation Pixelz, a pioneering platform in fashion e-commerce content creation, has made headlines with its innovative approach to Artificial Intelligence (AI) featuring Digital Twins. This groundbreaking solution empowers brands to produce stunning, campaign-quality imagery rapidly and with creativity, thanks to a unique collaboration with...
Continue Reading
Alstom's First Half Results for Fiscal Year 2024/25 Unveiled
Alstom's First Half Results Overview Alstom, a leading player in the transportation sector, recently shared significant updates regarding its performance in the first half of the fiscal year 2024/25. The presentation showcases their commitment to growth, innovation, and sustainability throughout the railway industry. Financial Highlights During this presentation, Alstom...
Continue Reading
Brooke Shields Leads 'Hearts of Heroes' Season 8
A New Face Shines on 'Hearts of Heroes' Buckle up, folks! Brooke Shields is strapping in for the eighth season of 'Hearts of Heroes,' the award-winning show spotlighting everyday champions and first responders. Premiering on July 11, this series lands a spot in ABC's Weekend Adventure block, thrusting Shields into the limelight as she takes the baton from previous hosts...
Continue Reading
Cytokinetics' MYQORZO® Gains Approval for Hypertrophic Cardiomyopathy
Cytokinetics' MYQORZO® Achieves NMPA Approval in China Cytokinetics, Incorporated (NASDAQ: CYTK) has exciting news—the approval of MYQORZO® (aficamten) by the China National Medical Products Administration (NMPA) for adults suffering from obstructive hypertrophic cardiomyopathy (oHCM). This milestone not only underscores the effectiveness of their innovative therapy...
Continue Reading